This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 25 studies, archived under the term: "donezepil"

Click here to filter this large number of results.

An MRI substudy of a donepezil clinical trial in mild cognitive impairment
A magnetic resonance imaging (MRI) study was conducted as part of an intervention study in subjects with amnestic mild cognitive impairment (aMCI) to assess donepezil’s treatment effect on brain atrophy. Adults with aMCI were randomly assigned to double-blind treatment with 10 mg/day donepezil hydrochloride or placebo for 48 weeks. Brain MRI scans were acquired at […]

Donepezil treatment in Alzheimer’s disease patients with and without cerebrovascular lesions: a preliminary report
Aim: Donepezil has not been evaluated in Korean patients with Alzheimer’s disease (AD) for up to 1 year. The objectives of this study were to evaluate the differential efficacy of donepezil in Korean AD patients with and without concomitant cerebrovascular lesions (CVL).; Methods: This study was a 48-week open-label trial of donepezil in patients with […]

Donepezil provides greater benefits in mild compared to moderate Alzheimer’s disease: implications for early diagnosis and treatment
We assessed the cognitive and functional outcomes of donepezil treatment in mild versus moderate Alzheimer’s disease (AD) patients. We performed a 6-month prospective, observational, multicenter study of the progression of cognitive and functionality abilities in a large sample patients with AD who initiated treatment with donepezil in monotherapy. According to baseline mini mental state examination […]

SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
Objective: To estimate the treatment effects of SB-742457 and donepezil in Alzheimer disease (AD) in a contemporary clinical trial.; Method: Randomized, controlled, parallel-group, exploratory study with a 4-week, single-blind, placebo run-in phase and 24-week, double-blind treatment phase. Primary endpoints were Clinician’s Interview-Based Impression of Change with caregiver input (CIBIC+) and the Alzheimer’s Disease Assessment Scale-cognitive […]

Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer’s disease: a phase IIb dose-finding study
AZD3480 is a selective agonist of the central α4β2 and α2β2 neuronal nicotinic cholinergic receptors (NNRs). Its effects on cognition were investigated in 567 patients with mild-to-moderate Alzheimer’s disease (AD) (Mini Mental State Examination [MMSE] 12-26). Mean baseline MMSE was 21 (SD ± 3.7), with 61% of patients having mild disease (MMSE 21-26). Mean age […]

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease
Background: Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer’s disease (AD), was developed to address the need for an additional treatment option for patients with advanced AD. This report, based on a pivotal phase 3 study, presents a detailed analysis of the safety and tolerability of increasing […]

Combination treatment in Alzheimer’s disease: results of a randomized, controlled trial with cerebrolysin and donepezil
Treatment with neurotrophic agents might enhance and/or prolong the effects of cholinesterase inhibitors (ChEIs) in Alzheimer’s disease (AD). We compared the safety and efficacy of the neurotrophic compound Cerebrolysin (10 ml; n=64), donepezil (10 mg; n=66) and a combination of both treatments (n=67) in mild-to-moderate (mini-mental state examination-MMSE score 12-25) probable AD patients enrolled in […]

Efficacy and safety of donepezil in patients with Alzheimer’s disease in assisted living facilities
The aim of this 12-week, open-label study was to determine the safety and efficacy of donepezil in participants with Alzheimer’s disease (AD) residing in assisted living facilities (ALFs). Participants received 5 mg donepezil daily for 6 weeks followed by 10 mg daily for 6 weeks. Primary and secondary outcomes were change from baseline in Mini-Mental […]

Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size
Background and Purpose: We sought to assess the efficacy and safety of donepezil in patients with vascular dementia (VaD) fulfilling National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences criteria.; Methods: This international, multicenter, 24-week trial was conducted from March 2003 to August 2005. Patients (N=974; mean age, 73.0 […]

The effect of donepezil in comparison with conventional treatment on cognitive functioning and the performance of the patient in a prospective cohort of patients with Alzheimer’s disease treated in routine clinical practice in Spain
Aims: Our aim was to perform a secondary analysis of a 12-month-long, non-blind, multi-centre prospective cost-of-illness study. The analysis assessed the effect of donepezil on cognitive functioning and the performance of patients with possible or probable Alzheimer’s disease, compared to that of other drugs for dementia.; Patients and Methods: A sample of 700 patients took […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us